Affiliation
Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UKIssue Date
2015-10
Metadata
Show full item recordAbstract
Hypoxia is a feature of most solid tumours and is associated with a poor prognosis. The hypoxic environment can reduce the efficacy of radiotherapy and some chemotherapeutics, and has been investigated extensively as a therapeutic target. The clinical use of hypoxia-targeting treatment will benefit from the development of a biomarker to assess tumour hypoxia. There are several possible techniques that measure either the level of oxygen or the tumour molecular response to hypoxia. The latter includes gene expression profiling, which measures the transcriptional response of a tumour to its hypoxic microenvironment. A systematic review identified 32 published hypoxia gene expression signatures. The methods used for their derivation varied, but are broadly classified as: (i) identifying genes with significantly higher or lower expression in cancer cells cultured under hypoxic versus normoxic conditions; (ii) using either previously characterised hypoxia-regulated genes/biomarkers to define hypoxic tumours and then identifying other genes that are over- or under-expressed in the hypoxic tumours. Both generated gene signatures useful in furthering our understanding of hypoxia biology. However, signatures derived using the second method seem to be superior in terms of providing prognostic information. Here we summarise all 32 published hypoxia signatures, discuss their commonalities and differences, and highlight their strengths and limitations. This review also highlights the importance of reproducibility and gene annotation, which must be accounted for to transfer signatures robustly for clinical application as biomarkers.Citation
Gene expression signatures as biomarkers of tumour hypoxia. 2015, 27 (10):547-60 Clin OncolJournal
Clinical OncologyDOI
10.1016/j.clon.2015.07.004PubMed ID
26282471Type
ArticleLanguage
enISSN
1433-2981ae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2015.07.004
Scopus Count
Collections
Related articles
- Hypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy.
- Authors: Yang L, West CM
- Issue date: 2019 Jan
- Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures.
- Authors: Di Giovannantonio M, Hartley F, Elshenawy B, Barberis A, Hudson D, Shafique HS, Allott VES, Harris DA, Lord SR, Haider S, Harris AL, Buffa FM, Harris BHL
- Issue date: 2025 Feb 12
- Lost in application: Measuring hypoxia for radiotherapy optimisation.
- Authors: Thiruthaneeswaran N, Bibby BAS, Yang L, Hoskin PJ, Bristow RG, Choudhury A, West C
- Issue date: 2021 May
- Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia.
- Authors: Haider S, McIntyre A, van Stiphout RG, Winchester LM, Wigfield S, Harris AL, Buffa FM
- Issue date: 2016 Jun 29
- HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
- Authors: Linge A, Lohaus F, Löck S, Nowak A, Gudziol V, Valentini C, von Neubeck C, Jütz M, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Buchholz F, Aust DE, Baretton GB, Thames HD, Dubrovska A, Alsner J, Overgaard J, Krause M, Baumann M, DKTK-ROG
- Issue date: 2016 Dec